缺血性卒中危险因素研究进展

李 雪玲1, 孙 娟*2
1、青海大学研究生院
2、青海大学附属医院

摘要


缺血性卒中（IS）具有高发病率、高致残率、高死亡率的特点，是全球范围内成年人致死、致残的主要原因之一。IS病因复杂，是多因素共同作用的结果。本文对IS的危险因素进行综述，旨在为临床IS的预防及治疗提供理论依据。

关键词


缺血性卒中；危险因素；研究进展

全文:

PDF


参考


[1]李茸，李小平.成年男性血红蛋白水平升高与空腹血糖、血尿酸及血脂检测结果分析[J].检验医学与临床.2020，17（02）：189-191.

[2]于婷婷，卢旺娣，孙青阳，等.正常人群同型半胱氨酸水平及相关因素分析[J].预防医学.2017，29（03）：248-250.

[3]Liu Z, Shen X, Li M, et al. Exploring the Nexus: How Ferroptosis, Microglia, and Neuroinflammation Converge in Ischemic Stroke Pathogenesis. Mol Neurobiol. 2025 Mar 10.

[4]Donkor ES. Stroke in the 21st Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. Stroke Res Treat. 2018 Nov 27;2018:3238165.

[5]Johnson W, Onuma O, Owolabi M, et al. Stroke: a global response is needed. Bull World Health Organ. 2016 Sep 1;94(9):634-634A.

[6]Hou S, Zhang Y, Xia Y, et al. Global, regional, and national epidemiology of ischemic stroke from 1990 to 2021. Eur J Neurol. 2024 Dec;31(12):e16481.

[7]Mehta SL, Manhas N, Raghubir R (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 54(1):34-66

[8]Fan J, Liu Y, Yin J, et al. Oxygen-Glucose-Deprivation/Reoxygenation-Induced Autophagic Cell Death Depends on JNK-Mediated Phosphorylation of Bcl-2. Cell Physiol Biochem. 2016;38(3):1063-74.

[9]Verkhratsky A, Nedergaard M. Physiology of astroglia[J]. Physiol Rev, 2018, 98(1):239-389.

[10]Ni XC, Wang HF, Cai YY, et al. Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke. Redox Biol. 2022 Aug;54:102363.

[11]Hasel P, Rose I, Sadick JS, et al. Neuroinflammatory astrocyte Subtypes in the mouse brain[J].Nat Neurosci, 2021, 24(10): 1475-1487.

[12]Cheng M, Liang XS, Shi LR, et al. Folic acid deficiency exacerbates the inflammatory response ofastrocytes after ischemia-reperfusion by enhancing the interaction between IL- 6 and JAK-1/pSTAT3[J].CNS Neurosci Ther, 2023, 29(6): 19.1537-1546.

[13]Androvic P, Kirdajova D, Tureckova J, et al. (2020). Decoding the transcriptional response to ischemic stroke in young and aged mouse brain. Cell Rep, 31:107777.

[14]Vyas MV, Silver FL, Austin PC, et al. Stroke incidence by sex across the lifespan. Stroke. 2021;52:447-451.

[15]Rehman S, Sahle BW, Chandra RV, et al. Sex differences in risk factors for aneurysmal subarachnoid haemorrhage: systematic review and meta-analysis. J Neurol Sci. 2019;406:116446.

[16]Maja Ramljak, Moises Freitas-Andrade, Baptiste Lacoste, et al. Glial cell interactions in neonatal hypoxic-ischemic injury, Glial Health Research, 2, (100006), (2025).

[17]Heron M. Deaths: leading causes for 2019. Natl Vital Stat Rep. 2021;70:1-114.

[18]Leening MJ, Ferket BS, Steyerberg EW, et al. Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ. 2014;349:g5992.

[19]Ji H, Kim A, Ebinger JE, et al. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020;5:19-26.

[20]Riise HKR, Sulo G, Tell GS, et al. Association between gestational hypertension and risk of cardiovascular disease among 617 589 Norwegian women. J Am Heart Assoc. 2018;7:e008337.

[21]Mishra SR, Chung HF, Waller M, et al. Association between reproductive life span and incident nonfatal cardiovascular disease: a pooled analysis of individual patient data from 12 studies. JAMA Cardiol. 2020;5:1410-1418.

[22]WANG Chenran, MENG Xianfeng, WANG Chunping, et al. Trends of burden on ischemic heart disease and epidemiological transition of related risk factors in China, 1990-2017[J]. Chinese Journal of Epidemiology, 2020, 41(10): 1703-1709.

[23]Floßmann, E.; Schulz, U.G.; Rothwell, P.M. Systematic Review of Methods and Results of Studies of the Genetic Epidemiology of Ischemic Stroke. Stroke 2004, 35, 212-227.

[24]Joutel, A.; Corpechot, C.; Ducros, A.; et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nat. Cell Biol. 1996, 383, 707-710.

[25]Bersano, A.; Markus, H.S.; Quaglini, S.; et al. Clinical Pregenetic Screening for Stroke Monogenic Diseases. Stroke 2016, 47, 1702-1709.

[26]Chabriat, H.; Joutel, A.; Dichgans, M.; et al. CADASIL. Lancet Neurol. 2009, 8, 643-653.

[27]Onodera, O.; Nozaki, H.; Fukutake, T. HTRA1 Disorder Summary Genetic Counseling GeneReview Scope. In GeneReviews®; University of Washington: Seattle, WA, USA, 2021; pp. 1-16.

[28]Nozaki, H.; Nishizawa, M.; Onodera, O. Features of Cerebral Autosomal Recessive Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke 2014, 45, 3447-3453.

[29]Fox, C.S.; Polak, J.F.; Chazaro, I.; et al. Genetic and Environmental Contributions to Atherosclerosis Phenotypes in Men and Women. Stroke 2003, 34, 397-401.

[30]Bernhardt, J.; Zorowitz, R.D.; Becker, K.; et al. Advances in Stroke 2017. Stroke 2018, 49, E174-E199.

[31]Diener HC, Hankey GJ. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. J Am Coll Cardiol. 2020 Apr 21;75(15):1804-1818.

[32]Cipolla MJ, Liebeskind DS, Chan SL. The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation. J Cereb Blood Flow Metab. 2018 Dec;38(12):2129-2149.

[33]Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289(19):2560-2571.

[34]M.R. Law, J.K. Morris, N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ, 338 (2009), p. b1665

[35]Maida, C.D.; Daidone, M.; Pacinella, G.; et al. Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases. Int. J. Mol. Sci. 2022, 23, 2397.

[36]Folsom, A.R.; Rasmussen, M.L.; Chambless, L.E.; et al. Prospective Associations of Fasting Insulin, Body Fat Distribution, and Diabetes with Risk of Ischemic Stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999, 22, 1077-1083.

[37]Kuusisto, J.; Mykkänen, L.; Pyörälä, K.; et al. Non-Insulin-Dependent Diabetes and Its Metabolic Control Are Important Predictors of Stroke in Elderly Subjects. Stroke 1994, 25, 1157-1164.

[38]Kopin L., Lowenstein C. Dyslipidemia. Ann. Intern. Med. 2017;167(11):ITC81-ITC96.

[39]Alloubani A, Nimer R, Samara R. Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review. Curr Cardiol Rev. 2021;17(6):e051121189015.

[40]Yaghi S, Elkind MS: Lipids and cerebrovascular disease: research and practice. Stroke. 2015, 46:3322-8.

[41]Curb JD, Abbott RD, Rodriguez BL, et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program. Am J Epidemiol. 2004, 160:150-7.

[42]Liang HJ, Zhang QY, Hu YT, et al. Hypertriglyceridemia: a neglected risk factor for ischemic stroke?. J Stroke. 2022, 24:21-40.

[43]Amarenco P., Bogousslavsky J., Callahan A., et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006;355(6):549-559.

[44]Mármol F, Sanchez J, Martínez-Pinteño A. Effects of uric acid on oxidative and nitrosative stress and other related parameters in SH-SY5Y human neuroblastoma cells. Prostaglandins Leukot Essent Fatty Acids. 2021;165:102237.

[45]Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. PLoS One. 2020 Feb 14;15(2):e0228684.

[46]Berry C, Hamilton CA, Brosnan MJ, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000 May 9;101(18):2206-12.

[47]Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005 Dec;16(12):3553-62.

[48]Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002 Dec;13(12):2888-97.

[49]Vannorsdall TD, Jinnah HA, Gordon B, et al. Cerebral ischemia mediates the effect of serum uric acid on cognitive function. Stroke. 2008 Dec;39(12):3418-20.

[50]Dimitroula HV, Hatzitolios AI, Karvounis HI. The role of uric acid in stroke: the issue remains unresolved. Neurologist. 2008 Jul;14(4):238-42.

[51]Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke. 2003 Aug;34(8):1951-6.

[52]Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed). 2012 Jan 1;17(2):656-69.

[53]Zhong C, Zhong X, Xu T, et al. Sex-Specific Relationship Between Serum Uric Acid and Risk of Stroke: A Dose-Response Meta-Analysis of Prospective Studies. J Am Heart Assoc. 2017 Mar 29;6(4):e005042.

[54]Kamei K, Konta T, Hirayama A, et al. Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study. Clin Exp Nephrol. 2017 Jun;21(3):497-503.

[55]Martin RC, Burgin WS, Schabath MB, et al. Gender-specific differences for risk of disability and death in atrial fibrillation-related stroke. Am J Cardiol. 2017;119(2):256-61.

[56]Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke - results from a population-based study. Stroke. 2005;36(6):1115-9.

[57]Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009 Jan 10;373(9658):155-66.

[58]Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian stroke registry. Eur Heart J. 2004;25(19):1734-40.

[59]Ko D, Rahman F, Schnabel RB, et al. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13(6):321-32.

[60]Bradley TD, Floras JS (2009) Obstructive sleep apnoea and its cardiovascular consequences. Lancet 373(9657):82-93.

[61]Dharmakulaseelan L, Boulos MI. Sleep Apnea and Stroke: A Narrative Review. Chest. 2024 Oct;166(4):857-866.

[62]Lyons O.D. Obstructive sleep apnea in the patient with atrial fibrillation: current knowledge and remaining uncertainties. Curr Opin Pulm Med. 2023;29:550-556.

[63]Javaheri S., Barbe F., Campos-Rodriguez F., et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69:841-858.

[64]Xu, H. et al. Association between obstructive sleep apnea and lipid metabolism during REM and NREM sleep. J. Clin. Sleep. Med.16, 475-482 (2020).

[65]Savransky V, Jun J, Li J, et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res. 2008 Nov 7;103(10):1173-80.

[66]Panwar B, Judd SE, Warnock DG, et al. Hemoglobin concentration and risk of incident stroke in community-living adults. Stroke. 2016, 47: 2017-24.

[67]Richard E, Desviat LR, Ugarte M, et al. Oxidative stress and apoptosis in homocystinuria patients with genetic remethylation defects[J]. J Cell Biochem. 2013, 114: 183-191.


Refbacks

  • 当前没有refback。